Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Fireman B.V. (IFRX)

Fireman B.V. (IFRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 120,121
  • Shares Outstanding, K 58,883
  • Annual Sales, $ 70 K
  • Annual Income, $ -46,180 K
  • EBIT $ -61 M
  • EBITDA $ -61 M
  • 60-Month Beta 1.57
  • Price/Sales 1,662.58
  • Price/Cash Flow N/A
  • Price/Book 1.57

Options Overview Details

View History
  • Implied Volatility 168.03% ( +3.10%)
  • Historical Volatility 84.50%
  • IV Percentile 33%
  • IV Rank 13.04%
  • IV High 832.82% on 01/23/24
  • IV Low 68.30% on 10/23/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 410
  • Volume Avg (30-Day) 341
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 5,027
  • Open Int (30-Day) 4,750

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.30
  • Number of Estimates 3
  • High Estimate -0.28
  • Low Estimate -0.31
  • Prior Year -0.30
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.45 +42.07%
on 10/22/24
2.44 -15.57%
on 11/14/24
+0.53 (+34.64%)
since 10/21/24
3-Month
1.36 +51.47%
on 09/11/24
2.44 -15.57%
on 11/14/24
+0.65 (+46.10%)
since 08/21/24
52-Week
1.16 +76.82%
on 05/08/24
2.44 -15.57%
on 11/14/24
+0.60 (+41.10%)
since 11/21/23

Most Recent Stories

More News
InflaRx N.V. Receives Positive CHMP Opinion for Marketing Authorization of GOHIBIC for COVID-19 Linked Acute Respiratory Distress Syndrome Treatment

The CHMP recommends marketing authorization for InflaRx's GOHIBIC to treat COVID-19 related ARDS in certain patients.Quiver AI SummaryInflaRx N.V. announced that the Committee for Medicinal Products for...

IFRX : 2.06 (+0.98%)
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the...

IFRX : 2.06 (+0.98%)
Stock Index Futures Move Higher Ahead of U.S. Inflation Data, Fed Minutes

June S&P 500 futures (ESM23) are up +0.28%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.21% this morning after three major U.S. benchmark indices finished the regular session mixed as market participants...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
CAT : 389.59 (+2.12%)
VOLVB.S.DX : 269.500 (+1.74%)
HTCR : 1.3000 (+4.84%)
HZON : 11.33 (+0.09%)
CFLT : 30.61 (+7.14%)
IFRX : 2.06 (+0.98%)
MDB : 315.44 (+11.95%)
Why InflaRx Stock Skyrocketed This Week

The biopharmaceutical company's near-term sales outlook has gotten a huge boost following Emergency Use Authorization for one of its drugs.

RJF : 163.78 (+0.99%)
IFRX : 2.06 (+0.98%)
Why Shares of InflaRx Are Soaring Wednesday

A key EUA from the FDA for the company's COVID-19 therapy gave the stock a jolt.

IFRX : 2.06 (+0.98%)
Stock Index Futures Move Lower as Recession Fears Weigh on Sentiment

June S&P 500 futures (ESM23) are down -0.22%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.23% this morning after three major U.S. benchmark indices finished the regular session lower as a swathe...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
CAT : 389.59 (+2.12%)
JPM : 244.76 (+1.65%)
SW.FP : 80.250 (-0.43%)
KRUS : 95.54 (+7.19%)
IFRX : 2.06 (+0.98%)
JNJ : 155.50 (+1.56%)
SGH : 20.85 (+0.43%)
BE : 23.94 (-3.47%)
CI : 330.07 (+2.07%)
InflaRx Reports Second Quarter 2022 Financial & Operating Results

Fast Track and Orphan Drug designation for vilobelimab in pyoderma gangrenosum (PG) granted by the FDAPlans to submit EUA with the FDA for vilobelimab in...

IFRX : 2.06 (+0.98%)
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients

Completed encouraging Type B meeting with US FDAApplication for EUA planned to be submitted in Q3 2022 JENA, Germany, July 26, 2022 (GLOBE NEWSWIRE) --...

IFRX : 2.06 (+0.98%)
InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum

US Food and Drug Administration awards Fast Track designation for the treatment of ulcerative pyoderma gangrenosumFast track follows recently reported...

IFRX : 2.06 (+0.98%)
InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19

Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMAProductive end-of-phase II meeting with FDA held for PG;...

IFRX : 2.06 (+0.98%)

Business Summary

InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany.

See More

Key Turning Points

3rd Resistance Point 2.31
2nd Resistance Point 2.23
1st Resistance Point 2.14
Last Price 2.06
1st Support Level 1.97
2nd Support Level 1.89
3rd Support Level 1.80

See More

52-Week High 2.44
Last Price 2.06
Fibonacci 61.8% 1.95
Fibonacci 50% 1.80
Fibonacci 38.2% 1.65
52-Week Low 1.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar